Looks like you clickedhttps://www.businesswire.com/news/home/20220927005159/en/Blue-Earth-Diagnostics-Announces-FDA-Acceptance-of-New-Drug-Application-for-18F-rhPSMA-7.3-a-Radiohybrid-Prostate-Specific-Membrane-Antigen-Targeted-PET-Imaging-Agent-for-Prostate-Cancer
If you do not want to visit that page, you can close this browser tab.
